Development of insulin resistance and elevated blood pressure during therapy with cyclosporine A

Blood Pressure

Volumn 6, Issue 1, 1997, Pages 13-17

  Kutkuhn, Bernd ^a   Hollenbeck, Markus ^a   Heering, Peter ^a   Koch, Michael ^a   Voiculescu, Adina ^a   Reinhard, Thomas ^a   Grabensee, Bernd ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

cyclosporine A; essential hypertension; insulin resistance

Indexed keywords

CYCLOSPORIN A;

ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INSULIN RESISTANCE; KERATOPLASTY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SIDE EFFECT;

EID: 0031015116     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.3109/08037059709086440     Document Type: Article

References (24)

1. Ferrannini E, Buzzigoli G, Bonadonna R. Insulin resistance in essential hypertension. New Engl J Med 1987; 317: 350-7.
2. Modan M, Halkin H, Almog S, Lusky A, Eshkol A, Shefi, M. Hyperinsulinemia. A link between hypertension, obesity and glucose intolerance. J Clin Invest 1985; 75: 809-17.
3. Swislocke AL, Hoffman BB, Reaven GM. Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension. Am J Hypertens 1989; 2: 419-23.
4. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131-41.
5. Fontbonne A, Charles MA, Thibult N, Richard JR, Claude JR, Warnet JM, Rosselin GE, Eschwege E. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991; 34: 356.
6. Curtis JJ, Luke R, Jonse P., Diethelm A. Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent. Am J Med 1988; 85: 134-8.
7. Sundmacher R, Reinhard T, Heering P. Six years experience with systemic cyclosporin A prophylaxis in high risk perforating keratoplasty patients. German J Ophthalmol 1992; 1: 432-6.
8. Bergman RN, Ider YZ, Bowden CR, Cobelli C. Quantitative estimation of insulin sensitivity. Am J Physiol 1979; 236: E667.
9. Yale JF, Chamelian M, Courchesne S, Vigeant C. Peripheral Insulin resistance and decreased Insulin secretion after ciclosporine A treatment. Transplant Proceed 1988; 3: 985-8.
10. Yale JF, Roy RD, Grose M, Seemayer TA, Murphy GF, Marliss EB. Effects of cyclosporine on glucose tolerance in the rat. Diabetes 1985; 34: 1309.
11. Dresner LS, Andersen DK, Kahng KU, Munshi IA, Wait RB. Effects of cyclosporine on glucose metabolism. Surgery 1989; 106; 163-9.
12. Wahlstrom HE, Lavelle-Jones M, Endres D, Akimoto R, Kolterman O, Moossa AR. Inhibition of insulin release by cyclosporine and production of peripheral insulin resistance in the dog. Transplantion 1990; 49: 600-4.
13. Esmatjes E, Ricart MJ, Ferres JP, Oppenhaimer F, Vilardell J, Casamitjana R. Cyclosporine's effect on insulin secretion in patients with kidney transplants. Transplantion 1991; 52: 500-3.
14. Ost L, Tyden G, Fehrman I. Impaired glucose tolerance in cyclosporine-prednisolone-treated renal graft recipients Transplantation 1988; 46: 370-2.
15. Mallion JM, De Gaudemaris R, Sich, JP, Maitre A, Pitiot M. Day and night blood pressure values in normotensive and essential hypertensive subjects assessed by twenty-four-hour ambulatory monitoring. J Hypertens 1990; 8 Suppl 6: 49-55.
16. Ballantyne CM, Podet EJ, Patsch WPÖ, Haraty Y, Appel V, Gotto AM Jr, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 7: 53-6.
17. Renlund DG, Bristow MR, Crandall BG, et al. Hypercholesterolemia after heart transplantation: amelioration by corticosteroid-free maintenance immunsuppression. J Heart Trans 1989; 3: 214-20.
18. Pearsons HG, Thirsk JE, Frohlich J, Dias V, Minuk GY. Effect of Cyclosporin A on serum lipids in primary biliary cirrhosis patients. Clin Invest Med 1989; 6: 386-91
19. Markell MS, Brown CD, Butt KMH, Friedman EA. Prospective Evaluation of changes in lipid profiles in cyclosporine-treated renal transplant patients. Transplant Proceed 1989; 1: 1497-9.
20. Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993; 21: 886-93.
21. Lönnroth P, Davies JI, Lönnroth I, Smith U. The interaction between the adenylate cyclase system and insulin-stimulation glucose transport. Evidence for the importance of both cyclic AMP-dependent and -independent mechanisms. Biochem J 1987; 243: 789-95.
22. Smith U, Kuroda M, Simpson IA. Counter-regulation of insulin-stimulated glucose transport by catecholamines in the isolated rat adipose cell. J Biol Chem 1984; 259: 8758-63.
23. Stadtmauer L, Rosen OM. Increasing the cAMP content of IM-9 cells alters the phosphoryladon state and protein kinase activity of the insulin receptor. J Biol Chem 1986; 261: 3402-7.
24. Scherrer U, Vissinig SF, Morgan BJ, Rollins JA, Tindall RSA, Ring S, Victor RG. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. New Engl J Med 1990; 11: 693-9.